The Auxiliary Effects of Low-Molecular-Weight Fucoidan in Locally Advanced Rectal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy Before Surgery: A Double-Blind, Randomized, Placebo-Controlled Study
| Autor: | Hsiang-Lin Tsai MD, PhD, Yung-Sung Yeh MD, Po-Jung Chen MD, Yu-Tang Chang MD, Yen-Cheng Chen MD, Wei-Chih Su MD, Tsung-Kun Chang MD, Ching-Wen Huang MD, PhD, Jaw-Yuan Wang MD, PhD |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Integrative Cancer Therapies, Vol 22 (2023) |
| Druh dokumentu: | article |
| ISSN: | 1552-695X 15347354 |
| DOI: | 10.1177/15347354231187153 |
| Popis: | Patients with cancer use low-molecular-weight fucoidan (LMF) as a supplement to therapy. However, most studies of LMF are in vitro or conducted using animals. Concurrent chemoradiotherapy (CCRT) is the gold standard for locally advanced rectal cancer (LARC). This study investigated the quality of life (QoL) and clinical outcomes of patients with LARC taking LMF as a supplement to neoadjuvant CCRT. This was a double-blind, randomized, placebo-controlled study. The sample comprised 87 patients, of whom 44 were included in a fucoidan group and 43 were included in a placebo group. We compared their QoL scores and clinical outcomes before treatment, and at 1 month, 2 months, and 3 months posttreatment. Pretreatment and posttreatment gut microbiota differences were also compared. Although enhanced physical well-being (PWB) at 2 months and 3 months posttreatment in the fucoidan group were observed (both P .0125). Skin rash and itching and fatigue were less common in the fucoidan group (both P |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|